To describe a cluster of severe myocarditis cases associated with parvovirus B19 infection in children during the post-COVID-19 period, highlighting the significance of this context.
Key Findings:
27 children were identified with parvovirus B19-associated myocarditis, with a significant increase in cases in 2024 compared to previous years.
93% of cases required intensive care, with 88% receiving inotropes and 15% requiring extracorporeal membrane oxygenation.
The median age of affected children was 21 months, with common symptoms including difficulty breathing and fatigue.
All cases tested positive for parvovirus B19 DNA in blood, with a median viral load indicating recent infection.
Interpretation:
The study highlights a concerning rise in severe myocarditis cases linked to parvovirus B19 in children, particularly in the context of increased viral circulation post-COVID-19, emphasizing the need for public health awareness.
Limitations:
Retrospective design may limit the comprehensiveness of data collection.
Potential for underreporting of cases prior to 2024 due to lower awareness or testing rates.
Bias in case identification may affect the reliability of the findings.
Conclusion:
The findings underscore the need for vigilant screening for parvovirus B19 in pediatric myocarditis cases, especially during periods of increased viral activity, and suggest specific actions for healthcare providers.
by Neal Russell, James Hatcher, Tim Best, Judith Breuer, James Charlesworth, Peter Muir, Barry Vipond, Stephane Paulus, Rohit Saxena, Jacob Simmonds, Stefania Vergnano, Peter Davis, Seilesh Kadambari
